BridgeMD
Phase 4, double-blind study evaluating the response on computed tomography (CT) lung density decline rates of Respreeza / Zemaira weekly for 3 years in adults with alpha1 antitrypsin deficiency (AATD)
EU CTIS ID: 2025-522964-33-00
What this study is testing
This is a study to primarily assess the ability of the 2 active doses of CE1226 (Respreeza / Zemaira) to influence the annual lung density decline rate as compared to the marketed dose of CE1226 in participants with AATD.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- • Age greater than or equal to (>=) 18 and less than or equal to (<=) 65 years at the time of providing written informed consent. • Confirmed diagnosis of emphysema related to AATD with either the PiZZ, PiZ(null), or Pi(null/null) genotype with documented serum AAT levels less than (<) 11 micrometer (μM) (or < 50 mg/dL [milligram/deciliter]) at any time before the first administration of CE1226 on Day 1 (Baseline).
You likely can't join if
- • Participants should not have acute illness or pulmonary exacerbation within 6 weeks before the first administration of CE1226 on Day 1 (Baseline). • Participants should not have previously received gene therapy for AATD at any point. • Participants with liver disease secondary to AATD.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.